Adamas Pharmaceuticals

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Adamas Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 8 completed later-stage tilt top decile by trial count

Adamas Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.

Adamas Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 7 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Levodopa Induced Dyskinesia (LID), with 2 trials.

Top-decile sponsor footprint

Adamas Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 3

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT03567057
COMPLETED Phase 3

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199
COMPLETED Phase 2

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT02471222
COMPLETED Phase 3

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

NCT02274766
TERMINATED Phase 3

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

NCT02153645
TERMINATED Phase 3

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632
COMPLETED Phase 3

Open-Label Safety Study of ADS-5102 in PD Patients With LID

NCT02202551
COMPLETED Phase 3

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

NCT02136914
COMPLETED Phase 2

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

NCT01397422
COMPLETED Phase 2

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 7

Therapeutic Areas

Levodopa Induced Dyskinesia (LID) 2
Dyskinesia 2
Parkinsons Disease (PD) 2
Influenza 1

How the Adamas Pharmaceuticals archive is shaped

10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).

Phase mix: 7 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Levodopa Induced Dyskinesia (LID) (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Adamas Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Adamas Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAimmune Therapeutics10xBio22nd Century Group23andMe3-C Institute for Social Development
Adamas Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Adamas Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Adamas Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Adamas Pharmaceuticals or any single study.

  • None of Adamas Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Levodopa Induced Dyskinesia (LID) is the condition Adamas Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Levodopa Induced Dyskinesia (LID) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Adamas Pharmaceuticals pipeline card: 10 registered trials from official public datasets.Report a data error.